MedTrace Logo

A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects

NCT02585440 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-02-02

No results posted yet for this study

Summary

This is a phase 1 study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels.

Conditions

Interventions

DRUG

CMX157

Oral tablet

DRUG

placebo

Oral tablet

Sponsors & Collaborators

  • ContraVir Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • John Sullivan-Bolyai, MD, MPH · ContraVir

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-08-31
Completion
2016-09-30

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02585440 on ClinicalTrials.gov